BidaskClub Upgrades Momenta Pharmaceuticals (MNTA) to Buy
BidaskClub upgraded shares of Momenta Pharmaceuticals (NASDAQ:MNTA) from a hold rating to a buy rating in a research report report published on Tuesday morning.
A number of other equities analysts also recently issued reports on MNTA. Cowen set a $15.00 target price on Momenta Pharmaceuticals and gave the stock a hold rating in a research note on Wednesday, November 1st. Zacks Investment Research downgraded Momenta Pharmaceuticals from a hold rating to a sell rating in a research note on Monday, December 4th. Finally, Stifel Nicolaus reissued a hold rating and set a $18.00 target price on shares of Momenta Pharmaceuticals in a research note on Tuesday, January 30th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the stock. The company presently has a consensus rating of Hold and an average price target of $15.30.
Momenta Pharmaceuticals (NASDAQ:MNTA) opened at $16.00 on Tuesday. The stock has a market capitalization of $1,220.00, a P/E ratio of -20.00 and a beta of 1.80. Momenta Pharmaceuticals has a one year low of $11.85 and a one year high of $19.46.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. increased its stake in Momenta Pharmaceuticals by 14.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,446 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 834 shares in the last quarter. LS Investment Advisors LLC increased its stake in Momenta Pharmaceuticals by 59.8% in the 4th quarter. LS Investment Advisors LLC now owns 9,300 shares of the biotechnology company’s stock valued at $130,000 after purchasing an additional 3,479 shares in the last quarter. Amalgamated Bank purchased a new position in Momenta Pharmaceuticals in the 4th quarter valued at approximately $152,000. Landscape Capital Management L.L.C. purchased a new position in Momenta Pharmaceuticals in the 4th quarter valued at approximately $159,000. Finally, Citigroup Inc. increased its stake in Momenta Pharmaceuticals by 263.2% in the 2nd quarter. Citigroup Inc. now owns 13,736 shares of the biotechnology company’s stock valued at $232,000 after purchasing an additional 9,954 shares in the last quarter. 93.01% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “BidaskClub Upgrades Momenta Pharmaceuticals (MNTA) to Buy” was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://theolympiareport.com/2018/02/14/bidaskclub-upgrades-momenta-pharmaceuticals-mnta-to-buy.html.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.